Daratumumab (Anti-CD38)
Based on 11 publication(s) in Google Scholar
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
For research use only. We do not sell to patients.
- Purity: 97.94%
- CAS No.: 945721-28-8
- Molecular Weight:145.26 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Daratumumab (Anti-CD38)
More- Nat Biotechnol. 2025 Oct 17. [Abstract]
- Nat Commun. 2025 Jun 3;16(1):5145. [Abstract]
- Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]
- J Med Chem. 2026 Mar 26;69(6):7068-7081. [Abstract]
- Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- Electrophoresis. 2026 Mar 24. [Abstract]
- Transfus Med. 2025 Apr 9. [Abstract]
- Blood Neoplasia. 2025 Oct 16;3(1):100174. [Abstract]
- bioRxiv. 2025 April 29.
- University of Palermo. 2025.
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
Human IgG1 kappa
Human
CD38
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Daratumumab (anti-CD38) (HY-P9915A). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 945721-28-8
-
Appearance Liquid
-
Molecular Weight 145.26 kDa
-
Color Colorless to light yellow
-
SMILES
[Daratumumab (Anti-CD38)]
-
Synonyms
Anti-Human CD38, Human Antibody (PBS)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Biotechnol
2025 Oct 17. PMID: 41107533
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2025 Oct 17. [Abstract]
A single mesodermal tumor was injected into mesodermal CAR-T cells, and the following treatments were administered: untreated group, daratumumab (0.5 or 10 μg/ml) treatment group, or IgG isotype control antibody (10 μg/ml IgG) treatment group. The change in T cell area over time was quantitatively analyzed.
-
Nat Commun
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth. [Abstract]2025 Jun 3;16(1):5145. PMID: 40461553 -
Clin Cancer Res
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. [Abstract]2023 Aug 15;29(16):2988-3003. PMID: 37265425
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]
ADCC capability of INBRX-109 was evaluated in the Promega Jurkat CD16a (V158) ADCC reporter assay using DR5-transfected ExpiCHO-S cells as targets and untransfected cells as negative controls. Daratumumab (5.5 h), the target of which is expressed on Jurkat cells, serves as a positive control.
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. [Abstract]
The ability of INBRX-109 to bind the complement component C1q contained within normal human serum was measured by ELISA. Daratumumab (5.5 h) is used as a positive control.
-
J Med Chem
CD38-Targeted Small-Molecule PET Radiotracer for Noninvasive Tumor Evaluation and Preliminary Therapy Monitoring in Multiple Myeloma. [Abstract]2026 Mar 26;69(6):7068-7081. PMID: 41837524 -
Cell Mol Life Sci
Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid. [Abstract]2025 Oct 7;82(1):352. PMID: 41055748
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
ADCC in H929 cells caused by various concentration of Dara (Daratumumab, 1h treatment and 4h NK cell co-culture).
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
Compared with vehicle control, Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w) cause significantly reduction of xenograft tumors weight and tumor growth.
Daratumumab (Anti-CD38) purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Oct 7;82(1):352. [Abstract]
Inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. Dara (Daratumumab, i.p. 8 mg/kg per mouse weekly for 3w).
-
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Transfus Med
Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing. [Abstract]2025 Apr 9. PMID: 40204650 -
Blood Neoplasia
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response. [Abstract]2025 Oct 16;3(1):100174. PMID: 41480309 -
-
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23. [Content Brief]
[2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)